At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
Earlier this year, at the annual Genitourinary Cancer symposium in San Francisco, we were first given information about the potential of three new tests for the diagnosis of prostate cancer: the so-called miR Sentinel tests from miR Scientific. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, exome, miR, sentinel, test, urine | 10 Comments »
We have recently learned that Movember conducted a major landscape analysis of unmet research needs in prostate cancer that started back in 2017 and ran through 2019 but just got published in 2020. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: analysis, landscape, Movember, need, priority, research | Leave a comment »
If you weren’t able to take part in the “live” presentation by Dr. Peter Carroll on “The past, present and future of active surveillance (AS)”, you can now view this either here on YouTube or here on the UroToday web site. This is the first in a series of four live video programs on AS-related topics. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance | 2 Comments »
We have heard from Howard Wolinksy that he and others have been helping to put together a series of four webinars on different aspects of active surveillance (AS) for the management of favorable-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance, webinar | 1 Comment »
A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: benefit, PSA, risk, screening, test | 4 Comments »
Slowly but surely we are learning more about the roles of family history and familial genetics (heredity) in determining risk for prostate cancer — and most especially risk for clinically significant forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: family, germline, heredity, history, mutation, risk | 3 Comments »
So even if we don’t want to think or talk about it, most of us are well aware that about 40 percent of all Americans are now obese. In other words, they have a body mass index (BMI) of 30 kg/m2 or higher. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: BMI, body, index, mass, mortality, weight | Leave a comment »
The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: consensus, germline, risk, somatic, testing | 1 Comment »
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 3 Comments »
